Cover Image
市場調查報告書

天花:開發平台分析

Smallpox - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 192826
出版日期 內容資訊 英文 70 Pages
訂單完成後即時交付
價格
Back to Top
天花:開發平台分析 Smallpox - Pipeline Review, H2 2017
出版日期: 2017年07月18日 內容資訊: 英文 70 Pages
簡介

所謂天花是因天花病毒造成的急性接觸感染症。主要的症狀有發熱、不舒服、頭痛、極度疲勞、激烈背痛、腹痛及嘔吐等。之後還會在臉、手、前臂及軀體產生皮疹。此外口、鼻黏膜也會產生病斑。潰瘍性的病斑會在口、喉嚨中放出大量病毒。

本報告提供天花治療藥的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

天花概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中產品概要

  • 後期階段的產品
  • 初期階段的產品
  • 未確認階段的產品

開發中的產品:各企業

開發中的產品:大學/研究機關別

開發治療藥的企業

  • Bavarian Nordic A/S
  • CEL-SCI Corporation
  • Chimerix, Inc.
  • EpiVax, Inc.
  • Nanotherapeutics, Inc.
  • Oncovir, Inc.
  • SIGA Technologies, Inc.
  • Symphogen A/S
  • TapImmune Inc.
  • Tonix Pharmaceuticals Holding Corp.

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介(產品說明·作用機制·R&D進展)

  • 24a
  • brincidofovir
  • CEL-1000
  • cidofovir
  • imatinib mesylate
  • Monoclonal Antibodies for Infectious Disease
  • PL-801
  • Poly-ICLC
  • small pox vaccine
  • smallpox vaccine
  • smallpox vaccine
  • Sym-002
  • tecovirimat
  • TPIV-300
  • VIR-002

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9559IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Smallpox - Pipeline Review, H2 2017, provides an overview of the Smallpox (Infectious Disease) pipeline landscape.

Smallpox is an acute contagious infection caused by the Variola virus. Symptoms include fever, malaise, headache, prostration, severe back pain, abdominal pain and vomiting. This is followed by the development of rashes on the face, hands, forearms and the trunk. Lesions develop in the mucous membranes of the nose and mouth which ulcerate, releasing large amounts of virus into the mouth and throat. Treatment includes medications such as antiviral and lifestyle modification.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Smallpox - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Smallpox (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Smallpox (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Smallpox and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 3, 6 and 3 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Smallpox (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Smallpox (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Smallpox (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Smallpox (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Smallpox (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Smallpox (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Smallpox (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Smallpox (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Smallpox - Overview
    • Smallpox - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Smallpox - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Smallpox - Companies Involved in Therapeutics Development
    • Bavarian Nordic A/S
    • BioFactura Inc
    • CEL-SCI Corp
    • Chimerix Inc
    • EpiVax Inc
    • SIGA Technologies Inc
    • Tonix Pharmaceuticals Holding Corp
  • Smallpox - Drug Profiles
    • 24a - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • brincidofovir - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CEL-1000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies for Infectious Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody for Smallpox - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NN-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PL-801 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SCV-305 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • smallpox [ankara] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • smallpox vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tecovirimat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TNX-801 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VIR-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Smallpox - Dormant Projects
  • Smallpox - Discontinued Products
  • Smallpox - Product Development Milestones
    • Featured News & Press Releases
      • Jun 16, 2017: Bavarian Nordic Announces Notification of Request for Proposal for Freeze-Dried IMVAMUNE
      • May 31, 2017: SIGA to Present at the Jefferies Global Healthcare Conference on June 9, 2017
      • Apr 20, 2017: SIGA Completes Enrollment and Dosing in Final Cohort of Phase I Study of IV Formulation of TPOXX (tecovirimat) to Treat Smallpox
      • Mar 02, 2017: Tonix Pharmaceuticals Announces Demonstrated Vaccine Activity in First-Ever Synthesized Chimeric Horsepox Virus
      • Jan 10, 2017: Tonix Pharmaceuticals Provides Update on TNX-801 at 9th Annual Biotech Showcase Conference
      • Jan 06, 2017: Chimerix Announces Preliminary Data from Ongoing Phase 1 Dose Escalation Study of Intravenous Brincidofovir in Healthy Subjects
      • Nov 23, 2016: Bavarian Nordic Completes Enrollment of Phase 3 Non-inferiority Study of IMVAMUNE Smallpox Vaccine
      • Sep 21, 2016: SIGA Announces Bankruptcy Court Approval of Transaction Under Which SIGA Will Pay PharmAthene Claim in Full
      • Jun 15, 2016: Bavarian Nordic Announces Expansion of IMVAMUNE Orders from Canadian Government
      • Feb 24, 2016: FDA Concurs on Clinical Dose for SIGA's Tecovirimat Antiviral
      • Feb 08, 2016: Chimerix Presents Positive Results From Brincidofovir Pivotal Study in Animal Model for Smallpox
      • Dec 24, 2015: Delaware Supreme Court Affirms Chancery Court Ruling in Favor of PharmAthene
      • Sep 14, 2015: Chimerix and BARDA Announce Contract Extension of $13.0 Million for the Continued Development of Brincidofovir for Smallpox
      • Jul 23, 2015: Chimerix Announces Positive Topline Results From Brincidofovir Pivotal Study in Animal Model for Smallpox
      • Jul 07, 2015: Bavarian Nordic Receives Order for IMVAMUNE Smallpox Vaccine from the U.S. Government Valued at USD 133 Million
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Smallpox, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Smallpox - Pipeline by Bavarian Nordic A/S, H2 2017
  • Smallpox - Pipeline by BioFactura Inc, H2 2017
  • Smallpox - Pipeline by CEL-SCI Corp, H2 2017
  • Smallpox - Pipeline by Chimerix Inc, H2 2017
  • Smallpox - Pipeline by EpiVax Inc, H2 2017
  • Smallpox - Pipeline by SIGA Technologies Inc, H2 2017
  • Smallpox - Pipeline by Tonix Pharmaceuticals Holding Corp, H2 2017
  • Smallpox - Dormant Projects, H2 2017
  • Smallpox - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Smallpox - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Smallpox, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top